Improving access to health products for people co-infected with HIV and HPV: UNITAID board passes resolution
8 June 2017: In recognition of the need to address some of the leading cause of death among people living with HIV in low- and middle-income countries, the board of Unitaid has passed a resolution to support improved access to health products for people with advanced HIV disease, those co-infected with HIV and hepatitis, as well as, people co-infected with HIV and HPV. This resolution presents an important step forward in ensuring the prevention and control of cervical cancer.
An estimated one million-plus women worldwide are currently living with cervical cancer. Many have no access to health services for prevention, curative treatment or palliative care. Cervical cancer is associated with infection by human papillomavirus (HPV).
Cervical cancer is one of the world’s deadliest – but most easily preventable – forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries. The second edition of WHO's guidelines were launched at the World Cancer Leaders’ Summit in Melbourne, Australia on 3 December 2014. These guidelines could mean the difference between life and death for girls and women worldwide.
Revised WHO position on human papillomavirus vaccines
24 October 2014 - In an updated position paper published today, WHO revised the number of doses recommended for human papillomavirus (HPV) vaccines for different age groups.
WHO reiterates its recommendation that HPV vaccines should be included in national immunization programmes, provided that: prevention of cervical cancer and other HPV-related diseases constitutes a public health priority; vaccine introduction is programmatically feasible; sustainable financing can be secured; and the cost-effectiveness of vaccination strategies in the country or region is considered.